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ABSTRACT  
Objective: To study the physicochemical and microbiological stability of phenytoin sodium extemporaneous suspension. Methods: The 
extemporaneous suspension was prepared from the prompt release capsules of phenytoin sodium (100 mg/capsule). Four capsules 
were uncapped and the granules were ground into fine powders using a mortar and pestle. The powders were dispersed in sugar-free 
suspension structured vehicle to achieve the concentration of 10 mg/mL. The suspensions were stored in glass and polyethylene plastic 
bottles and kept at 4, 25, and 40 ºC. The percent initial drug remaining, pH, sedimentation volume, viscosity, X-ray-powder 
diffractometry and microbial stability were evaluated. Results: The percent phenytoin sodium concentration remained above 90% of 
initial concentration up to 56 days at all temperatures. The pH of suspensions were rather constant in both glass and polyethylene 
containers. The sedimentation volumes were 0.39 - 0.41 and redispersibilities were 3.3 - 3.5 throughout the study. The rheology of 
prepared suspension exhibited a shear-thining system. The X-ray powder diffractogram showed that sediment of phenytoin sodium in 
sugar-free suspension structured vehicle was in free acid form and no change in polymorphic form was observed after storage at 25 ºC 
for 56 days. Conclusion: The extemporaneous suspension was chemically stable up to 56 days at 4, 25, and 40 ºC. The prepared 
suspension met USP specification in microbial examination of nonsterile product after storage at 25 ºC for 56 days.   
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Introduction 
§Phenytoin is an effective anticonvulsant drug which was 
used mainly in the prophylactic management of tonic-clonic 
seizues and partial seizues with complex symtomatology. It 
is also used for the prevention and treatment of seizures 
occurring during surgery.1 The usual initial oral dosage of 
phenytoin for treatment of seizures in children is 5 mg/kg or 
250 mg/m2 daily administered in 2 or 3 equally divided 
doses. Total dosage should not exceed 300 mg daily and 
maintenance dosage for treatment is required.2 Furthermore, 
phenytoin can be used in neonates, infants and children with 
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seizures. In the U.S. market, phenytoin is available in 
various dosage forms such as prompt release tablets and 
capsules, extended release capsules, injection and 
suspensions. However, the oral suspensions of phenytoin 
are not commercially available in many countries which 
constitute a small market such as some countries in Europe 
and Thailand. Therefore it is necessary to prepare an oral 
liquid dosage form from prompt releases tablets or capsules 
by dispersing or dissolving in a suitable vehicle. These are 
referred to as extemporaneously prepared formations.3 
Because most drugs are not completely soluble, 
suspensions are generally extemporaneously prepared. The 
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extemporaneous oral liquid suspensions should be easily 
prepared, allow dosage flexibility and ensure palatability. The 
commercially available suspending vehicles, eg. Ora-Sweet®, 
Ora-Sweet SF®, Ora-plus®, Ora-Blend® and SyrSpend SF®, 
are widely used to prepare extemporaneous suspensions. 
However, since these vehicles are occasionally not stocked 
in a hospital, hospital pharmacists must prepare a vehicle for 
extemporaneous preparation. The combination of viscosity 
enhancing agent, sweetening agent and preservative is used 
to prepare a vehicle providing a good physical, chemical and 
microbiological stability. Carboxymethylcellulose methyl-
cellulose and xanthan gum are generally used as 
suspending agent due to its desirable rheological behavior.4 
In practice, the documented stability data are used to 
determine the beyond-use date of extemporaneous 
preparation.5 However, a major problem of many extemp-
oraneous preparations is due to a lack of information 
regarding suitability and stability.6 If the stability information 
is not available, the USP suggested the beyond-use date of 
14 days if stored in a refrigerator.7 Since there was a lack of 
stability information of phenytoin extemporaneous 
preparation, a study of the stability of such preparation is 
required. Additionally, phenytoin is usually dispensed to 
patients continuously for maintenance therapy. If 
extemporaneous phenytoin preparation is stable longer than 
14 days, less frequent dispensing is required. The patient 
will benefit from more convenience and reduced medication 
error.  
The purpose of this study was to determine the 
physicochemical stability and microbial stability of an 
extemporaneous phenytoin suspension when stored at 4, 25 
and 40 ºC. In this study, the sugar-free suspension 
structured vehicle, recommended in USP 26/NF 21, was 
used to disperse drug granules due to simple preparation 
technique needed and good palatability offerred.8 The 
percent initial drug remaining, pH, sedimentation volume, 






Materials and Methods 
Chemicals and reagents 
Capsules containing 100 mg of pheytoin sodium 
(commercial available in Thailand) were used. Xanthan gum 
and hydrocortisone were obtained from Sigma (USA). 
Sorbitol and mannitol were purchased from Ajax Finechem 
(New Zealand). Potassium sorbate and citric acid anhydrous 
were supplied by Fluka (USA). Glycerin and saccharin 
sodium were provided from P.C. Drug Center Co, Ltd, 
Thailand. Potasium dihydrogen phosphate was from Carlo 
Erba, Italy. Methanol was of HPLC grade (Labscan, 
Thailand). Other reagents were analytical grade and 
purchased from Merck, Germany.  
 
 Extemporaneous preparation 
The sugar-free suspension structured vehicle was 
prepared according to the USP 26/NF 21. The vehicle 
consists of 0.20% xanthan gum, 0.20% saccharin sodium, 
0.15% potassium sorbate, 0.10% citric acid, 2.0% sorbitol, 
2.0% mannitol, 2% glycerin and purified water qs. to 100 mL. 
The extemporaneous oral suspension was prepared using 
prompt release capsules containing 100 mg of phenytoin 
sodium. Four capsules were uncapped and the granules 
were ground into fine powder in a mortar. The fine powder 
was dispersed in a sugar-free suspension structured vehicle 
to achieve a concentration of 10 mg/mL. The suspensions 
were stored in glass and polyethylene plastic bottles and 
kept at 4, 25, and 40 ºC. All samples were protected from 
light. 
 
Physicochemical stability test 
Analytical method  
The content of phenytoin sodium was determined with a 
modification of previous reports.9,10 A liquid chromatograph 
system (Perkin Elmer Instruments, USA) equipped with a C-
18 HPLC column (Hypersil 25 cm x 4.6 cm, Thermoscientific, 
England) was used. The mobile phase consisted of MeOH : 
50 mM phosphate buffer (55:45) adjusted with 2 M 
phosphoric acid to pH 4 at a flow rate of 1 ml/min. The UV-
VIS detector was operated at 235 nm. Hydrocortisone was 
used as an internal standard. The relationship of peak area 
ratio between phenytoin sodium at concentrations of 40, 80, 
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120, 160 and 200 μg/mL and hydrocortisone at 
concentration of 32 μg/mL was plotted as a standard curve. 
The method validation was determined for specificity, 
precision, accuracy, linearity, limit of detection (LOD) and 
limit of quantification (LOQ).  
 
Drug analysis 
The extemporaneous suspensions were sampled on days 
0, 7, 14, 21, 28 and 56. After gentle shaking, 1 ml of the 
extemporaneous suspension was pipetted into a 100-mL 
volumetric flask. The solution of hydrocortisone solution (1 
mg/mL, 3.2 mL) was added, followed by addition of mobile 
phase up to 100 mL. The mixture was sonicated about 10 
min and filtered through a 0.45 μm nylon membrane filter. 
Twenty μL of this filtered sample was injected onto HPLC 
column. All samples for each storage condition were 
assayed in four replicates. The initial concentration (day 0) of 
phenytoin sodium was designated as 100%. The phenytoin 
sodium concentration at each time point was expressed as a 
percentage of the initial concentration. A sample was 
considered stable if percentage of phenytoin sodium was 
above 90% of the initial concentration.11,12 
 
pH measurement 
The pH of extemporaneously prepared suspension was 
measured using pH meter (Orion®, USA) on days 0, 7, 14, 
21, 28 and 56. The pH 4.0 and pH 7.0 standard buffer 
solutions (Thermo Electron Corporation, USA) were used to 
calibrate the pH meter. 
 
Sedimentation volume 
The extemporaneous suspensions were kept in a 100-ml 
graduated cylinder at 25 ºC after preparation. The sediment 
of suspensions was measured on days 7, 14, 21, 28 and 56. 
The sedimentation volume was calculated as F = Vu/Vo; 
where F = sedimentation volume, and Vu and Vo = volume of 




The redispersibility was determined with a slight 
modification from the method of Bhargava and colleagues.13 
The extemporaneous suspension in a 100-ml glass cylinder 
was rotated through 135º and turned back at the same 
position. The end point was taken when the base of the 
graduated cylinder was free from sediment. The number of 
rotation was recorded. 
 
Viscosity 
The extemporaneous suspension was kept at 25 ºC and 
the viscosity was determined on days 0, 28 and 56. The 
viscosity was measured using Brookfield Viscometer (Model 
DV-II+, Brookfield Engineering Lab, Inc, USA) using LV 
spindle No.1 at speeds of 20, 50, and 100 rpm.  
 
X-ray powder diffraction (XRD) 
Phenytoin sodium was weighed and dispersed in a sugar-
free suspension structured vehicle to yield a concentration of 
10 mg/mL. The suspension was kept at 25 ºC and analyzed 
on days 0 and 56. The suspension was centrifuged at 
10,000 rpm for 2 hours using a high speed centrifugation 
(Tomy, Japan). The supernatant was discarded and the 
sediment was kept in an oven (Mammert, Germany) at 40 ºC 
for about 2 days until dried. The sample was ground using 
an agate mortar and pestle then placed in a cavity of the 
sample holder of X-ray diffractometer. X-ray diffraction 
patterns of samples were obtained using X-ray diffractometer 
(JEOL, Japan) over a range of 5-60º, 2θ angle, with a step 
angle of 0.02. The X-ray powder diffraction patterns of 
phenytoin and phenytoin sodium powder were also recorded 
to compare with that of the sediment.  
  
Microbial stability test 
Microbial test of extemporaneous suspension stored at 25 
ºC was performed on days 28 and 56, according to 
monograph microbiological examination of nonsterile 
products.14 The extemporaneous suspension was diluted 
with Casein-Peptone Lecithin Polysorbate Broth (PLPB) in a 
dilution of 1:10. A portion of diluted suspension was then 
streaked on the Tryptic Soy Agar (TSA) plate for bacteria 
determination. The petri-dish was incubated at 30 – 35 ºC 
for 3 - 5 days to observe bacteria. For yeast and mould 
determination, the extemporaneous suspension was diluted 
with PLPB in a dilution of 1:10, then streaked on the 
Sabouraud-Dextrose Agar (SDA) plate. The petri-dish was 
incubated at temperature 20 – 25 ºC for 5 - 7 days to 
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observe yeasts and moulds. For determination of 
Escherichia coli (E. coli), the extemporaneous suspension 
was also diluted with PLPB in a dilution of 1:10. Ten mL of 
diluted suspension was used to inoculate in 100 mL Tryptic 
Soy Broth (TSB), mixed, and incubated at 35 – 37 ºC for 18 
- 48 hours. One mL of inoculated TSB was transferred to 
100 mL of MacConkey Broth (MCB), incubated at 43 – 45 ºC 
for 18 - 24 hours. Then, the broth was subcultured on a 
plate of MacConkey Agar (MCA) at 35 – 37 ºC for 18 - 72 
hours. The growth of colonies indicates the possible 
presence of E. coli.  
The microbial count was considered to be the average 
number of colony-forming units (cfu) found in agar. The 
experiment was performed in duplicate. Based on 
USP31/NF26, the microbial quality of non-sterile dosage 
forms for oral use meets requirements with a total aerobic 
microbial counts of less than 200 cfu/ml, a total combined 
yeasts/moulds of less than 20 cfu/ml and the absence of 
E.coli.14 
 
Results and Discussion  
 
Physicochemical Stability  
Drug Analysis 
The HPLC technique was suitable for determination of 
phenytoin sodium. Under the condition used, the retention 
time of phenytoin sodium and hydrocortisone were 7.6 - 7.8 
min and 9.4 - 9.5 min, respectively. The excipients in sugar-
free suspension structured vehicle were also separated. The 
peaks at 2.7 - 2.8 min and 5.6 - 5.9 min were attributed to 
saccharin sodium and potassium sorbate, respectively 
(Figure 1). The standard curve was linear and the coefficient 
of determination for the standard curve (r2) was 0.9989 - 
0.9999 for the entire study. The intra-day and inter-day 
coefficients of variation were less than 2% at each 
concentration of three replicates. The limit of detection was 
0.5 μg/mL (signal to noise ratio of 3:1) while limit of 
quantification was 2 μg/mL (signal to noise ratio of 10:1). 
The validation data indicated that our method was 
appropriate for analytical assay.15 The analytical results 
showed that the percent phenytoin sodium concentration 
remained above 90% of the initial concentration after storage 
for 56 days at 4, 25 and 40 ºC in both glass and 
polyethylene plastic containers. The percent of initial 
concentrations were in a range of 94.39 - 104.15% as shown 
in Figures 2 and 3. The previous study reported that the loss 
of phenytoin during nasogastric administration was attributed 
to a binding interaction between phenytoin and plastic 
tubing.16 However, our data showed that the loss of 
phenytoin was not observed in polyethylene plastic. 
Furthermore, the percent remaining of phenytoin sodium was 
more than 90% at 40 ºC throughout 56 days indicating that 
phenytoin sodium was stable at high temp erature. This is 
consistent with previous report that phenytoin is very stable 
even under conditions of extreme stress. After refluxing 
phenytoin in 2.5 N HCl for seven hours, essentially complete 
recovery of phenytoin was obtained.17 
 
pH measurement 
It was found that pH of sugar-free suspension structured 
vehicle was about 4.1 - 4.2. The 10 mg/mL phenytoin 
sodium extemporaneous prepared suspension was a white 
and readily redispersible suspension. The pH of phenytoin 
sodium suspension increased to 10.58 - 10.66 after freshly  
 
 
Figure 1 HPLC chromatogram of phenytoin sodium 
extemporaneous suspension representing 
saccharin sodium (peak A), potassium sorbate 
(peak B), phenytoin sodium (peak C) and 





























Figure 2 Percentage of initial concentration of 10 mg/mL 
phenytoin sodium extemporaneous preparation 
(mean ± SD, n = 4) after storage in glass container 
at 4 °C (•), 25 °C (■) and 40 °C (▲) on days 7, 
























Figure 3 Percentage of initial concentration of 10 mg/mL 
phenytoin sodium extemporaneous preparation 
(mean ± SD, n = 4) after storage in polyethylene 
plastic container at 4 °C (•), 25 °C (■) and 40 °C 
(▲) on days 7, 14, 21, 28, 42 and 56.  
 
 
Table 1 pH of phenytoin sodium extemporaneous suspensions in glass and polyethylene plastic container at 4, 25 and 40 ºC 






Temp 4 ºC Temp 25 ºC Temp 40 ºC 
 
Temp 4 ºC Temp 25 ºC Temp 40 ºC 
0 10.66 ± 0.01 10.62 ± 0.05 10.62 ± 0.01 
 
10.58 ± 0.03 10.61 ± 0.04 10.63 ± 0.05 
7 10.71 ± 0.01 10.64 ± 0.04 10.32 ± 0.01 
 
10.67 ± 0.01 10.63 ± 0.04 10.34 ± 0.08 
14 10.68 ± 0.02 10.60 ± 0.04 10.31 ± 0.04 
 
10.65 ± 0.02 10.61 ± 0.04 10.33 ± 0.07 
21 10.69 ± 0.02 10.55 ± 0.04 10.31 ± 0.05 
 
10.63 ± 0.01 10.53 ± 0.05 10.33 ± 0.07 
28 10.62 ± 0.01 10.47 ± 0.05 10.26 ± 0.02 
 
10.56 ± 0.02 10.44 ± 0.04 10.33 ± 0.08 
42 10.67 ± 0.01 10.50 ± 0.06 10.35 ± 0.02 
 
10.60 ± 0.01 10.51 ± 0.06 10.41 ± 0.07 
56 10.70 ± 0.02 10.48 ± 0.07 10.38 ± 0.02 
 
10.65 ± 0.01 10.50 ± 0.05 10.41 ± 0.08 
  
       
prepared. The increase of the pH was attributed to sodium 
salt of the drug. The pH values were rather constant in a 
range of 10.26 - 10.71 after storage for 56 days (Table 
1).However, the pH slightly decreased after storage at 40 ºC. 
The data indicated that type of container did not affect pH. 
Since pH of the preparation was higher than pKa of the drug 
(8.3 at 25 ºC)17, the higher pH of the system than pKa could 
result in a higher proportion of ionized form which might 
cause bitter taste. Addition of buffer system in the vehicle to 
control pH of suspension to about 6 or 7 was one of the 




Sedimentation volume and redispersibility  
The sedimentation volumes were between 0.39 and 0.41 
and redispersibilities were in a range of 3.3 - 3.5 (Table 2). 
The sedimentation volumes and redispersibility were 
relatively constant at 25 ºC throughout 56 days indicating 
that suspension was easily redispersed to yield uniform 
suspension. Additionally, no caking was observed. This 
result indicated that the sugar-free suspension structured 
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Table 2 Sedimentation volume and redispersibility of 
phenytoin sodium extemporaneous suspensions on 
days 7, 14, 21, 28, 42, 56 at 25 °C (mean ± SD, n 
= 4).  
Day Sedimentation  
volume (F) 
Redispersibility 
7 0.41 ± 0.01 3.3 ± 0.5 
14 0.40 ± 0.01 3.3 ± 0.5 
21 0.40 ± 0.01 3.3 ± 0.5 
28 0.40 ± 0.01 3.5 ± 0.6 
42 0.40 ± 0.01 3.5 ± 0.5 




After storage at 25 ºC for 56 days, the viscosities were not 
significantly different from the freshly prepared suspensions 
at the same speed of needle (Table 3). The viscosity 
decreased with increasing speed of needle indicating that 
the prepared suspension exhibited a shear thinning behavior. 
This result is in accordance with previous reports that 
xanthan gum exhibits plastic or pseudoplastic flow.13,18 This 
behavior was possibly a result of shearing action on the long 
chain molecule of xanthan gum. As the shearing stress is 
increased, the disarranged molecules start to align their long 
axes in the direction of flow. This orientation reduces the 
resistance which further allows lowering of viscosity at 
increasing shearing stress.19 Additionally, the viscosity of 
xanthan gum is independent of pH and temperature.18 
 
Table 3 Viscosity of phenytoin sodium extemporaneous 
suspension on days 0, 28, 56 at 25 °C (mean ± SD, 
n = 4).   
Viscosity (cps) at various speeds Day 
20 rpm 50 rpm 100 rpm 
0 44.6 ± 1.1 35.0 ± 1.0 28.7 ± 1.1 
28 45.6 ± 1.6 36.4 ± 0.7 29.4 ± 1.7 
56 42.5 ± 3.0 34.7 ± 0.3 27.8 ± 0.4 
 
 
X-ray powder diffraction  
Vehicle could have influence on the habit of crystalline 
materials which affect physicochemical characteristics and 
other properties such as manufacturability, dissolution rate 
and absorption rate. The study of X-ray diffractogram (XRD) 
was to evaluate possible polymorphic modification of drug in 
vehicle.20 XRD spectra of pure phenytoin sodium and 
phenytoin are presented in Figures 4A and 4B. According to 
XRD of phenytoin sodium powder, sharp peaks at diffraction 
angles of 2θ 8.64º, 11.40º, 13.02º, 16.60º, 17.33º, 18.52º, 
20.42º, 22.48º, 26.20º and 27.86º were present. The peaks 
of phenytoin powder were exhibited at 8.56º, 11.30º, 12.94º, 
16.56º, 17.26º, 20.34º, 22.40º, 26.12º, and 27.40º. The data 
suggested that both phenytoin and phenytoin sodium powder 
are crystalline material. The diffractogram of sediment 
corresponding to pure phenytoin is shown in Figure 4C. This 
indicated that the sediment of phenytoin sodium in sugar-
free suspension structured vehicle was in free acid form. 
Additionally, there was no significant difference in the 
diffraction pattern between XRD spectra of the sediment on 
day 0 and day 56, indicating that no polymorphic 
modification occurred due to vehicle influence (Figures 4C 
and 4D).  
 
 























Figure 4 X-ray diffractograms of phenytoin sodium powder 
(A), phenytoin powder (B), sediment of phenytoin 
sodium on day 0 (C), and sediment of phenytoin 
sodium on days 56 (D).  
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Microbial Stability   
Microbial contamination in nonsterile liquid formulations 
may cause foul odor, turbidity, and adversely effect 
palatability and appearance. High level of microorganisms 
may be hazardous to health especially in 
immunocompromised patients. By-product of microorganism 
metabolism may cause a change in the pH of the 
preparation and reduce the chemical stability.3 The use of 
preservative is required to control microbial growth during 
the beyond-use date in extemporaneous preparations. In this 
study, potassium sorbate was used as a preservative in the 
sugar-free suspension structured vehicle. The microbial 
stability study showed that the fungal contaminations of 5 
cfu/ml were detected on days 28 and 56. No bacteria or E. 
coli contamination was observed on both days 28 and 56. 
This indicated that phenytoin sodium extemporaneous 
suspension met the USP specifications in microbial 
examination of nonsterile product throughout 56 days.14 
Although our prepared suspension was in accordance with 
the acceptance criteria of microorganism qualification, the 
use of antimicrobial preservatives in formulation should be 
reconsidered. This is because the final pH of prepared 
extemporaneous suspension was higher than pKa of 
potassium sorbate (4.8) so that the ionized form of 
potassium sorbate was predominant.16 Therefore, the 
addition of other preservatives such as parabens or the use 
of buffer system to control final pH of prepared suspension 
was suggested to ensure good microbiological stability.  
 
Conclusions  
Phenytoin sodium is stable in a sugar-free suspension 
structured vehicle, allowing a fairly long beyond use date. 
The prepared extemporaneous suspension was chemically 
stable up to 56 days in all temperatures (4, 25 and 40 ºC) 
both in glass and polyethylene containers. The pH and 
appearance of suspension remained constant throughout the 
study. The rheology of suspension exhibited a shear-thinning 
system. The XRD indicated that the sediment of phenytoin 
sodium in vehicle was in free acid form and no polymorphic 
change was observed throughout 56 days. Additionally, 
phenytoin extemporaneous suspension met the USP 
specifications in microbial examination of nonsterile product. 
However, the use of buffer system to control final pH of 
prepared suspension was suggested to reduce bitter taste of 
drug and ensure good microbial stability.    
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